- Home
- JMM vs ACRV Comparison
JMM vs ACRV Comparison
Compare JMM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMM | ACRV |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5M | 47.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | JMM | ACRV |
|---|---|---|
| Price | $5.78 | $1.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 17.1K | ★ 864.7K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $691.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.68 | $1.05 |
| 52 Week High | $6.52 | $5.65 |
Technical Indicators
Market Signals| Indicator | JMM | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 49.01 |
| Support Level | $5.77 | $1.49 |
| Resistance Level | $6.39 | $1.86 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 10.81 | 66.18 |
Price Performance
Historical ComparisonAbout JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.